-
公开(公告)号：US10392443B2
公开(公告)日：2019-08-27
申请号：US15315597
申请日：2015-06-02
Applicant: Agency for Science, Technology and Research
Inventor： Sayan Chakraborty , Wanjin Hong
IPC: A61K39/395 , C07K16/30 , C07K16/18 , A61K31/7105 , A61K31/713 , G01N33/574 , C07K16/32 , C12N15/113
Abstract: Disclosed is a method for determining the likelihood of the presence or progression of a hepatocellular carcinoma in a subject, comprising determining the level of extracellular form of Agrin in an extracellular fluid obtained from the subject. Also disclosed are the use of anti Agrin agent for therapy, a pharmaceutical composition comprising anti-Agrin agent, a method of treating cancer comprising an anti-Agrin agent, a use of anti-Agrin agent and a kit thereof.
-
Patent Agency Ranking
公开(公告)号：US09316654B2
公开(公告)日：2016-04-19
申请号：US13919129
申请日：2013-06-17
Inventor： Wanjin Hong , Siew Wee Chan
IPC: G01N33/574 , A61K39/395 , G01N33/68 , C07K16/18 , C12N5/09 , C12N15/113
CPC classification number: G01N33/6893 , C07K16/18 , C12N5/0693 , C12N15/113 , C12N2310/111 , C12N2310/14 , C12N2503/02 , G01N33/57415
Abstract: We provide an anti-TAZ agent for the treatment, prophylaxis or alleviation of cancer. We further provide a kit for detecting breast cancer in an individual or susceptibility of the individual to breast cancer comprising means for detection of TAZ expression in the individual or a sample taken from him or her as well as a method of detecting a cancer cell, the method comprising detecting modulation of expression, amount or activity of TAZ in the cell.
-
公开(公告)号：US20130338028A1
公开(公告)日：2013-12-19
申请号：US13919129
申请日：2013-06-17
Inventor： Wanjin Hong , Siew Wee Chan
IPC: G01N33/68
CPC classification number: G01N33/6893 , C07K16/18 , C12N5/0693 , C12N15/113 , C12N2310/111 , C12N2310/14 , C12N2503/02 , G01N33/57415
Abstract: We provide an anti-TAZ agent for the treatment, prophylaxis or alleviation of cancer. We further provide a kit for detecting breast cancer in an individual or susceptibility of the individual to breast cancer comprising means for detection of TAZ expression in the individual or a sample taken from him or her as well as a method of detecting a cancer cell, the method comprising detecting modulation of expression, amount or activity of TAZ in the cell.
Abstract translation: 我们提供抗TAZ药物治疗，预防或减轻癌症。 我们进一步提供用于检测个体对乳腺癌或个体对乳腺癌的易感性的试剂盒，其包括用于检测个体中TAZ表达的手段或者取自他或她的样品以及检测癌细胞的方法 方法包括检测细胞中TAZ的表达，量或活性的调节。
-
公开(公告)号：US20230257435A1
公开(公告)日：2023-08-17
申请号：US18014449
申请日：2021-06-23
Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
Inventor： Sayan Chakraborty , Wanjin Hong
CPC classification number: C07K14/4725 , A61P17/02 , A61K38/00
Abstract: The present disclosure provides a pharmaceutical composition comprising an Agrin fragment or derivative thereof, and uses of the pharmaceutical composition. The present disclosure also provides method of producing the pharmaceutical composition.
-
公开(公告)号：US10398752B2
公开(公告)日：2019-09-03
申请号：US15550768
申请日：2016-02-11
Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
Inventor： Wanjin Hong , Shixiong Tan , Weiping Han
Abstract: The present disclosure describes to a method of treating a metabolic disease in a subject, wherein the method comprises administration of dermatopontin to a subject, wherein the dermatopontin is recombinant dermatopontin and the metabolic disease is selected from a group consisting of weight gain, diet-induced weight gain, obesity, morbid obesity, metabolic syndrome, glucose homeostasis, insulin resistance, type I diabetes, type if diabetes and cardiovascular disease. Disclosed herein is also a method of determining or making a prognosis of a subject's susceptibility to metabolic diseases and obesity, the method comprising measuring the level of circulating dermatopontin in a sample obtained from a subject; and comparing the level of circulating dermatopontin obtained with the level of dermatopontin previously determined in a control; and determining the susceptibility of the subject to metabolic disease and obesity based on the difference between the level of circulating dermatopontin and the level of dermatopontin in the control.
-
公开(公告)号：US20170198055A1
公开(公告)日：2017-07-13
申请号：US15315597
申请日：2015-06-02
Applicant: Agency for Science, Technology and Research
Inventor： Sayan Chakraborty , Wanjin Hong
IPC: C07K16/30 , G01N33/574 , C07K16/32 , C12N15/113
CPC classification number: C07K16/303 , A61K31/7105 , A61K31/713 , C07K16/18 , C07K16/3015 , C07K16/32 , C07K2317/24 , C07K2317/34 , C07K2317/76 , C07K2317/77 , C12N15/1135 , C12N15/1138 , C12N2310/14 , C12N2310/531 , G01N33/57415 , G01N33/57438 , G01N2333/4722
Abstract: Disclosed is a method for determining the likelihood of the presence or progression of a hepatocellular carcinoma in a subject, comprising determining the level of extracellular form of Agrin in an extracellular fluid obtained from the subject. Also disclosed are the use of anti Agrin agent for therapy, a pharmaceutical composition comprising anti-Agrin agent, a method of treating cancer comprising an anti-Agrin agent, a use of anti-Agrin agent and a kit thereof.
-
-
-
-
-
Search Results
6
records
(took 0.025 seconds)
